Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | VHL | P40337 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991504 | 1.00 | ATM (0.61) | ATMACEMMEVHLMEN1 | |
| SCHEMBL6933806 | 1.00 | ATM (0.61) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1334793 | 0.83 | ATM (0.59) | ATMACEMMEVHLMEN1 | |
| SCHEMBL4255907 | 0.83 | ATM (0.65) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1335205 | 0.83 | ATM (0.59) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1334597 | 0.83 | ATM (0.59) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1334796 | 0.83 | ATM (0.59) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1334899 | 0.83 | ATM (0.59) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1334691 | 0.83 | ATM (0.59) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1334690 | 0.83 | ATM (0.59) | ATMACEMMEVHLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1239204-C | Conjugates for the treatment of prostate cancer | MERCK & CO INC (US) | 2006-02-01 | — | — | CN | disclosed |
| EP-1009420-B1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO INC (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-0942754-B1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO INC (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-0942754-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5948750-A | OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN (PSA) AND KNOWN CYTOTOXIC AGENTS ARE DISCLOSED. SUCH CONJUGATES ARE USEFUL IN THE TREATMENT OF PROSTATIC CANCER AND | MERCK & CO., INC. (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1998018493-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 1998-05-07 | — | — | WO | disclosed |